I disagree that a reformulation is a reason for a pullback. On the contrary, it is a reason for the stock to go UP.

Kevetrin in an oral form is a huge plus. It makes administration much easier and cheaper and will enable multiple doses per day -- which would be hard on the patient if it's in IV-administered form.

Likewise, formulating Brilacidin-OM into an easy-to-mix sachet, thus enabling patients to conveniently store a weeks-long supply (instead of having to store multiple bottles of a pre-mixed version) is a huge step forward. It will also make it easier for pharmacies to store quantities of this, as it will not take up more space.

The attempt to paint these steps forward as steps back is utterly wrong.